|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
122,563,000 |
Market
Cap: |
6.59(B) |
Last
Volume: |
8,264,325 |
Avg
Vol: |
8,242,049 |
52
Week Range: |
$26.88 - $108.06 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
138,093 |
288,980 |
461,958 |
926,280 |
Total Sell Value |
$8,135,395 |
$19,867,810 |
$25,677,895 |
$46,442,456 |
Total People Sold |
7 |
8 |
8 |
12 |
Total Sell Transactions |
11 |
21 |
41 |
87 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Blum Robert I |
President |
|
2006-07-17 |
4 |
AS |
$5.46 |
$27,481 |
D/D |
(4,998) |
65,000 |
|
- |
|
Blum Robert I |
President |
|
2006-07-17 |
4 |
OE |
$0.58 |
$2,899 |
D/D |
4,998 |
69,998 |
|
- |
|
Sabry James H |
President and CEO |
|
2006-07-03 |
4 |
AS |
$6.51 |
$45,777 |
D/D |
(7,000) |
0 |
|
- |
|
Sabry James H |
President and CEO |
|
2006-07-03 |
4 |
OE |
$0.58 |
$4,060 |
D/D |
7,000 |
7,000 |
|
- |
|
Blum Robert I |
President |
|
2006-06-30 |
4 |
AS |
$6.61 |
$33,017 |
D/D |
(4,995) |
65,000 |
|
- |
|
Blum Robert I |
President |
|
2006-06-30 |
4 |
OE |
$0.58 |
$2,897 |
D/D |
4,995 |
69,995 |
|
- |
|
Spudich James A |
Director |
|
2006-06-29 |
4 |
AS |
$6.49 |
$14,278 |
D/D |
(2,200) |
229,000 |
|
- |
|
Blum Robert I |
President |
|
2006-06-15 |
4 |
AS |
$6.93 |
$34,581 |
D/D |
(4,990) |
65,000 |
|
- |
|
Blum Robert I |
President |
|
2006-06-15 |
4 |
OE |
$0.58 |
$2,894 |
D/D |
4,990 |
69,990 |
|
- |
|
Morgans David J Jr |
SVP-Drug Discovery and Dev |
|
2006-06-15 |
4 |
AS |
$6.93 |
$34,650 |
D/D |
(5,000) |
45,000 |
|
- |
|
Morgans David J Jr |
SVP-Drug Discovery and Dev |
|
2006-06-15 |
4 |
OE |
$0.58 |
$20,500 |
D/D |
30,000 |
50,000 |
|
- |
|
Sabry James H |
CEO |
|
2006-06-13 |
4 |
GD |
$0.00 |
$0 |
I/I |
10,500 |
199,500 |
|
- |
|
Trautman Jay K |
VP, Research |
|
2006-06-09 |
4 |
AS |
$7.03 |
$7,030 |
D/D |
(1,000) |
27,054 |
|
- |
|
Sabry James H |
President and CEO |
|
2006-06-01 |
4 |
AS |
$6.81 |
$48,250 |
D/D |
(7,000) |
0 |
|
- |
|
Sabry James H |
President and CEO |
|
2006-06-01 |
4 |
OE |
$0.58 |
$4,060 |
D/D |
7,000 |
7,000 |
|
- |
|
Blum Robert I |
President |
|
2006-05-30 |
4 |
AS |
$7.06 |
$35,159 |
D/D |
(4,980) |
65,000 |
|
- |
|
Blum Robert I |
President |
|
2006-05-30 |
4 |
OE |
$0.58 |
$2,888 |
D/D |
4,980 |
69,980 |
|
- |
|
Spudich James A |
Director |
|
2006-05-22 |
4 |
AS |
$7.25 |
$16,025 |
D/D |
(2,200) |
231,200 |
|
- |
|
Blum Robert I |
President |
|
2006-05-15 |
4 |
AS |
$6.94 |
$34,696 |
D/D |
(4,961) |
65,000 |
|
- |
|
Blum Robert I |
President |
|
2006-05-15 |
4 |
OE |
$0.58 |
$2,877 |
D/D |
4,961 |
69,961 |
|
- |
|
Morgans David J Jr |
SVP-Drug Discovery and Dev |
|
2006-05-15 |
4 |
AS |
$7.03 |
$35,150 |
D/D |
(5,000) |
20,000 |
|
- |
|
Morgans David J Jr |
SVP-Drug Discovery and Dev |
|
2006-05-15 |
4 |
OE |
$1.20 |
$6,000 |
D/D |
5,000 |
25,000 |
|
- |
|
Trautman Jay K |
VP, Research |
|
2006-05-10 |
4 |
AS |
$7.87 |
$7,870 |
D/D |
(1,000) |
28,054 |
|
- |
|
Blum Robert I |
EVP, Corp. Development & CBO |
|
2006-05-01 |
4 |
AS |
$7.10 |
$34,978 |
D/D |
(4,922) |
65,000 |
|
- |
|
Blum Robert I |
EVP, Corp. Development & CBO |
|
2006-05-01 |
4 |
OE |
$0.58 |
$2,855 |
D/D |
4,922 |
69,922 |
|
- |
|
1115 Records found
|
|
Page 41 of 45 |
|
|